Estrogen-mediated upregulation of Noxa is associated with cell cycle progression in estrogen receptor-positive breast cancer cells

PLoS ONE

Volumn 6, Issue 12, 2011, Pages

  Liu, Wensheng ^a   Swetzig, Wendy M ^a,b   Medisetty, Rajesh ^a,c   Das, Gokul M ^a,b  

^a UNIVERSITY AT BUFFALO   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c DR REDDY'S LABORATORIES LTD   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; ESTROGEN RECEPTOR ALPHA; MYC PROTEIN; PROTEIN NOXA; PROTEIN P53; SMALL INTERFERING RNA; ESTROGEN; PMAIP1 PROTEIN, HUMAN; PROTEIN BCL 2;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; ESTROGEN ACTIVITY; GENE; HUMAN; HUMAN CELL; NOXA GENE; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; TRANSCRIPTION REGULATION; UPREGULATION; BREAST TUMOR; CELL CYCLE; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; ESTROGEN RECEPTOR ALPHA; ESTROGENS; HUMANS; PROTO-ONCOGENE PROTEINS C-BCL-2; TRANSCRIPTION, GENETIC; UP-REGULATION;

EID: 84055216977     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0029466     Document Type: Article

References (47)

1. Oda E, Ohki R, Murasawa H, Nemoto J, Shibue T, et al. (2000) Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 288: 1053-1058.
2. Adams JM, Cory S, (2007) The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 26: 1324-1337.
3. Hetz C, Glimcher L, (2008) The daily job of night killers: alternative roles of the BCL-2 family in organelle physiology. Trends Cell Biol 18: 38-44.
4. Ploner C, Kofler R, Villunger A, (2008) Noxa: at the tip of the balance between life and death. Oncogene 27 (Suppl 1): S84-92.
5. Shibue T, Taniguchi T, (2006) BH3-only proteins: integrated control point of apoptosis. Int J Cancer 119: 2036-2043.
6. Letai AG, (2008) Diagnosing and exploiting cancer's addiction to blocks in apoptosis. Nat Rev Cancer 8: 121-132.
7. Dewson G, Kluck RM, (2010) Bcl-2 family-regulated apoptosis in health and disease. Cell Health and Cytoskeleton 2: 9-22.
8. Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, et al. (2005) Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 17: 393-403.
9. Cheng EH, Wei MC, Weiler S, Flavell RA, Mak TW, et al. (2001) BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol Cell 8: 705-711.
10. Kim H, Rafiuddin-Shah M, Tu HC, Jeffers JR, Zambetti GP, et al. (2006) Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies. Nat Cell Biol 8: 1348-1358.
11. Willis SN, Chen L, Dewson G, Wei A, Naik E, et al. (2005) Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev 19: 1294-1305.
12. Gomez-Bougie P, Wuilleme-Toumi S, Menoret E, Trichet V, Robillard N, et al. (2007) Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma. Cancer Res 67: 5418-5424.
13. Willis SN, Adams JM, (2005) Life in the balance: how BH3-only proteins induce apoptosis. Curr Opin Cell Biol 17: 617-625.
14. Elgendy M, Sheridan C, Brumatti G, Martin SJ, (2011) Oncogenic Ras-induced expression of Noxa and Beclin-1 promotes autophagic cell death and limits clonogenic survival. Mol Cell 42: 23-35.
15. Kutuk O, Arisan ED, Tezil T, Shoshan MC, Basaga H, (2009) Cisplatin overcomes Bcl-2-mediated resistance to apoptosis via preferential engagement of Bak: critical role of Noxa-mediated lipid peroxidation. Carcinogenesis 30: 1517-1527.
16. Ploner C, Rainer J, Lobenwein S, Geley S, Kofler R, (2009) Repression of the BH3-only molecule PMAIP1/Noxa impairs glucocorticoid sensitivity of acute lymphoblastic leukemia cells. Apoptosis 14: 821-828.
17. Lowman XH, McDonnell MA, Kosloske A, Odumade OA, Jenness C, et al. (2010) The proapoptotic function of Noxa in human leukemia cells is regulated by the kinase Cdk5 and by glucose. Mol Cell 40: 823-833.
18. Gimenez-Cassina A, Danial NN, (2010) Noxa: a sweet twist to survival and more. Mol Cell 40: 687-688.
19. Michalak EM, Villunger A, Adams JM, Strasser A, (2008) In several cell types tumour suppressor p53 induces apoptosis largely via Puma but Noxa can contribute. Cell Death Differ 15: 1019-1029.
20. Zinkel S, Gross A, Yang E, (2006) BCL2 family in DNA damage and cell cycle control. Cell Death Differ 13: 1351-1359.
21. Schuler M, Green DR, (2001) Mechanisms of p53-dependent apoptosis. Biochem Soc Trans 29: 684-688.
22. Nikiforov MA, Riblett M, Tang WH, Gratchouck V, Zhuang D, et al. (2007) Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition. Proc Natl Acad Sci U S A 104: 19488-19493.
23. Kim JY, Ahn HJ, Ryu JH, Suk K, Park JH, (2004) BH3-only protein Noxa is a mediator of hypoxic cell death induced by hypoxia-inducible factor 1alpha. J Exp Med 199: 113-124.
24. Lallemand C, Blanchard B, Palmieri M, Lebon P, May E, et al. (2007) Single-stranded RNA viruses inactivate the transcriptional activity of p53 but induce NOXA-dependent apoptosis via post-translational modifications of IRF-1, IRF-3 and CREB. Oncogene 26: 328-338.
25. Hershko T, Ginsberg D, (2004) Up-regulation of Bcl-2 homology 3 (BH3)-only proteins by E2F1 mediates apoptosis. J Biol Chem 279: 8627-8634.
26. Carroll JS, Meyer CA, Song J, Li W, Geistlinger TR, et al. (2006) Genome-wide analysis of estrogen receptor binding sites. Nat Genet 38: 1289-1297.
27. Tozlu S, Girault I, Vacher S, Vendrell J, Andrieu C, et al. (2006) Identification of novel genes that co-cluster with estrogen receptor alpha in breast tumor biopsy specimens, using a large-scale real-time reverse transcription-PCR approach. Endocr Relat Cancer 13: 1109-1120.
28. Colditz GA, (1998) Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer. Journal of the National Cancer Institute 90: 814-823.
29. Henderson IC, (1993) Risk factors for breast cancer development. Cancer 71: 2127-2140.
30. Pike MC, Krailo MD, Henderson BE, Casagrande JT, Hoel DG, (1983) 'Hormonal' risk factors, 'breast tissue age' and the age-incidence of breast cancer. Nature 303: 767-770.
31. Jordan VC, (2007) Chemoprevention of breast cancer with selective oestrogen-receptor modulators. Nature reviews Cancer 7: 46-53.
32. McGuire WL, (1978) Hormone receptors: their role in predicting prognosis and response to endocrine therapy. Seminars in oncology 5: 428-433.
33. Dubik D, Shiu RP, (1988) Transcriptional regulation of c-myc oncogene expression by estrogen in hormone-responsive human breast cancer cells. J Biol Chem 263: 12705-12708.
34. Greasley PJ, Bonnard C, Amati B, (2000) Myc induces the nucleolin and BN51 genes: possible implications in ribosome biogenesis. Nucleic Acids Res 28: 446-453.
35. Bajic VB, Tan SL, Chong A, Tang S, Strom A, et al. (2003) Dragon ERE Finder version 2: A tool for accurate detection and analysis of estrogen response elements in vertebrate genomes. Nucleic Acids Res 31: 3605-3607.
36. Perillo B, Sasso A, Abbondanza C, Palumbo G, (2000) 17beta-estradiol inhibits apoptosis in MCF-7 cells, inducing bcl-2 expression via two estrogen-responsive elements present in the coding sequence. Mol Cell Biol 20: 2890-2901.
37. Stender JD, Frasor J, Komm B, Chang KC, Kraus WL, et al. (2007) Estrogen-regulated gene networks in human breast cancer cells: involvement of E2F1 in the regulation of cell proliferation. Mol Endocrinol 21: 2112-2123.
38. Johnson DG, Schwarz JK, Cress WD, Nevins JR, (1993) Expression of transcription factor E2F1 induces quiescent cells to enter S phase. Nature 365: 349-352.
39. Wong JV, Dong P, Nevins JR, Mathey-Prevot B, You L, (2011) Network calisthenics: Control of E2F dynamics in cell cycle entry. Cell Cycle 10: 3086-3094.
40. Wang Z, Sun Y, (2008) Identification and characterization of two splicing variants of human Noxa. Anticancer Res 28: 1667-1674.
41. Bretz J, Garcia J, Huang X, Kang L, Zhang Y, et al. (2011) Noxa mediates p18INK4c cell-cycle control of homeostasis in B cells and plasma cell precursors. Blood 117: 2179-2188.
42. Diallo JS, Aldejmah A, Mouhim AF, Peant B, Fahmy MA, et al. (2007) NOXA and PUMA expression add to clinical markers in predicting biochemical recurrence of prostate cancer patients in a survival tree model. Clin Cancer Res 13: 7044-7052.
43. Mackus WJ, Kater AP, Grummels A, Evers LM, Hooijbrink B, et al. (2005) Chronic lymphocytic leukemia cells display p53-dependent drug-induced Puma upregulation. Leukemia 19: 427-434.
44. Schuler M, Maurer U, Goldstein JC, Breitenbucher F, Hoffarth S, et al. (2003) p53 triggers apoptosis in oncogene-expressing fibroblasts by the induction of Noxa and mitochondrial Bax translocation. Cell Death Differ 10: 451-460.
45. Shibue T, Takeda K, Oda E, Tanaka H, Murasawa H, et al. (2003) Integral role of Noxa in p53-mediated apoptotic response. Genes Dev 17: 2233-2238.
46. Sayeed A, Konduri SD, Liu W, Bansal S, Li F, et al. (2007) Estrogen receptor alpha inhibits p53-mediated transcriptional repression: implications for the regulation of apoptosis. Cancer Research 67: 7746-7755.
47. Liu W, Konduri SD, Bansal S, Nayak BK, Rajasekaran SA, et al. (2006) Estrogen receptor-alpha binds p53 tumor suppressor protein directly and represses its function. J Biol Chem 281: 9837-9840.